Latest news with #TadaImages
Yahoo
16-06-2025
- Business
- Yahoo
Snowflake, Acxiom Partner To Power Secure AI Marketing For Brands
Snowflake (NYSE:SNOW) and Interpublic Group of Companies, Inc. (NYSE:IPG) owned Acxiom on Monday announced a partnership to build and deliver a modern, AI-powered marketing data infrastructure that will fundamentally transform how brands leverage AI for marketing. This collaboration will enable IPG to bring its proprietary data, identity, and collaboration tools directly into brands' Snowflake environments. With operations in over 100 countries, IPG will make these capabilities available to brands will help modernize outdated data practices by delivering a secure and transparent AI-powered marketing foundation built natively in the cloud. As part of this transformation, Acxiom will also modernize its products, solutions, and client environments with Snowflake, enabling brands to maximize the power of their first-party data in the cloud. This collaboration unlocks a new era of marketing capabilities for brands, the company said in a press release. Bringing IPG's advanced technologies, including Acxiom's comprehensive suite of data and identity solutions and IPG's collaborative Interact platform, directly into their Snowflake environments, brands gain unprecedented visibility and control over their data flow across applications, agencies, and platforms. With Snowflake's built-in privacy and security features, this direct integration eliminates the need to move first-party data. It empowers brands with real-time insights, precise audience segmentation, and improved personalization while modernizing their data and technology stacks with composable architectures and AI. Piper Sandler analyst Brent Bracelin called Snowflake one of their 'highest conviction growth ideas' for 2025. It is backed by the accomplishment of the 'Rule of 50,' which means 25% product revenue growth alongside 25% free cash flow margins at over $4 billion in annual recurring revenue. Price Action: SNOW stock is trading higher by 0.86% to $209.98 premarket at last check Monday. Read Next:Photo by Tada Images via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? SNOWFLAKE (SNOW): Free Stock Analysis Report THE INTERPUBLIC GROUP (IPG): Free Stock Analysis Report This article Snowflake, Acxiom Partner To Power Secure AI Marketing For Brands originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
11-06-2025
- Health
- Yahoo
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy. It is now approved for adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:ENTA) and developed and commercialized by this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate. HCV is a highly infectious blood-borne disease affecting the liver. The United States is expected to incur around $120 billion in total medical costs over the next 10 years through 2035 linked to chronic liver disease and other related conditions caused by untreated HCV. Data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Mavyret eight-week treatment in adults with acute HCV infection supported the label expansion. The study results showed Mavyret to be a highly efficacious treatment for people with acute HCV. The majority of the adverse events reported were mild or moderate in severity. Fatigue, asthenia, headache, and diarrhea were the most common adverse events. In 2017, the FDA approved Mavyret to treat adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis. In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6). Price Action: ABBV stock is trading higher by 1.54% to $192.43 at last check Wednesday. Read Next:Photo by Tada Images via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Business
- Yahoo
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained
Cellectar Biosciences, Inc. (NASDAQ:CLRB) stock is trading higher on Wednesday. As per data from Benzinga Pro, session volume stands at 361.96 million versus an average volume of 968.03k. What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company's iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).Why It Matters: WM is the dominant subtype of lymphoplasmacytic lymphoma. Data from the Phase 2 CLOVER WaM study, including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2%, which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented during the 66th Annual American Society of Hematology Conference in December 2024. As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation and Orphan Drug Designation. The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I 131 for r/r WM and PRIME Designation for WM. What's Next: Separately, the company has provided the EMA with a data package that includes extensive supportive preclinical, regulatory, and manufacturing data and safety and efficacy data from the CLOVER WaM Phase 2b clinical trial. The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval. In late July 2025, the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application. Price Action: CLRB stock is trading higher by 57.9% to $0.43 at last check Wednesday. Read Next:Photo by Tada Images via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
14-05-2025
- Entertainment
- New York Post
Gen Z co-opted the smiley face emoji, but beware — it means something totally different to them
Smiling at Gen Z? Better watch your back. What used to be the universal symbol of warmth and joy has taken a sinister turn — at least in the eyes of Gen Z. The classic smiley face emoji now means something completely different to those under 30. Instead of conveying happiness, the grinning yellow face is now seen as dismissive, passive-aggressive, or straight-up sarcastic. And if you're sending it to younger colleagues or friends, it could be rubbing them the wrong way. Hafeezat Bishi, a 21-year-old intern, recently told the Wall Street Journal that she was taken aback when her older coworkers used the smiley emoji in emails and texts. 4 Flashing a smile at Gen Z? Brace yourself. The classic symbol of warmth and friendliness has morphed into something far snarkier — at least to them. Emojipedia 'I had to remember they are older, because I use it sarcastically,' Bishi said, explaining that she often views the emoji as conveying a 'side-eye smile' rather than genuine enthusiasm. Meanwhile, Sara Anderson, a 31-year-old cheerleading coach, told the outlet that she regularly includes the emoji to add 'lightness' to her messages. But that's exactly the disconnect — what seems friendly to older folks can come off as phony or even biting to the younger crowd. According to Erica Dhawan, author of 'Digital Body Language: How to Build Trust and Connection, No Matter the Distance,' older generations tend to take emojis at face value, while younger 'digital natives' assign entirely different meanings. 4 Author Erica Dhawan says older folks read emojis by the book — but for Gen Z, those little icons pack a whole new punch. Tada Images – 'People over 30 tend to use emoji according to their dictionary,' Dhawan told the Journal, emphasizing that for Gen Z, emoji meanings have evolved into a whole new lexicon. But the generational gap isn't just about smileys. Back in March, Amit Kalley, founder of mom-and-dad support site For Working Parents, warned that emojis have become a covert language for teens to communicate everything from drug slang to hate speech. 'It's far from an exhaustive list, but it's based on common emojis used to say something very different to what you'd think,' Kalley wrote on Instagram, pointing to a 'periodic table of emojis' that decodes the hidden messages. 4 What looks like a friendly emoji to boomers and millennials? To Gen Z, it could mean a fake smile or a not-so-subtle jab. DisobeyArt – And the emoji evolution doesn't end there. A recent study from Oklahoma State University found that emoji use can reveal a lot more about your personality than you might think. Researchers surveyed 285 undergraduates, mostly 20-year-olds, to see how their emoji habits aligned with personality traits. 4 To Gen Z, that classic smiley face emoji isn't all sunshine — it's more of a smug, side-eye smirk that can come off as passive-aggressive in texts like above. 'Emoji use may be related to strategies to manipulate the perceptions of others and to present a positive impression of oneself,' the study said, suggesting that what you send could say more about you than you realize. So, the next time you slap a smiley face emoji on a message to Gen Z, think twice — it might not come off as cheery as you'd hoped.
Yahoo
13-05-2025
- Automotive
- Yahoo
What's Going On With NIO Stock On Tuesday?
NIO Inc. (NYSE:NIO) shares are trading lower on Tuesday. The firm revealed that its advanced steer-by-wire system, featured in the ET9 executive sedan, has secured a key regulatory approval in Europe, reports CnEV Post, citing a statement from CEO William Li on Weibo. This development positions the electric vehicle manufacturer as a global frontrunner in deploying next-generation driving technologies. The SBW technology on the ET9 has received the E-Mark certification under the United Nations Economic Commission for Europe framework, following assessment by the Spanish automotive certification group Applus marks the first time the organization has endorsed an SBW-enabled vehicle in the region. NIO launched the ET9, its most premium offering to date, during Nio Day 2024. Priced at RMB 788,000 (approximately $109,560), the four-seater sedan began reaching customers in China at the end of March, CnEV Post adds. The company delivered 810 units in April, its first full delivery month, according to CnEVPost data. Alongside the ET9 milestone, NIO is refreshing several key models in its lineup. Beginning May 10, customers in China can place pre-orders for updated versions of the ES6 SUV, EC6 coupe SUV, and the ET5 and ET5 Touring sedans. Showrooms will simultaneously unveil the revamped ES6 and EC6 models. NIO recorded 23,900 vehicle deliveries in April, a 53% year-over-year increase. The surge in shipments indicates strong demand, even as the company invests in innovative features like SBW and explores international market opportunities. Price Action: NIO shares are trading lower by 2.02% to $4.115 at last check on Tuesday. Photo by Tada Images via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NIO (NIO): Free Stock Analysis Report This article What's Going On With NIO Stock On Tuesday? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
